Intravenous Ketamine for Treatment-Resistant Depression

Abroad (travel likely)RecruitingPHASE2

Conditions

Depressive Disorder, Treatment-Resistant · Treatment Resistant Depression (TRD)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Mayo Clinic in Rochester, Rochester, Minnesota, United States
Contact: Principal Investigator (Balwinder Singh)

Study leads

Balwinder Singh, M.D., M.S.
Principal Investigator
Mayo Clinic

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

Suicide · Depressive Disorder, Treatment-Resistant · Ketamine

Abroad (travel likely)RecruitingPHASE2

Bethesda, United States

Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

Depression and Quality of Life · Treatment Resistant Depression (TRD) · Anhedonia

Abroad (travel likely)Recruiting

Genova, Italy · Genova, Italy

University of Iowa Interventional Psychiatry Service Patient Registry

Treatment Resistant Depression · Major Depressive Episode · Major Depression

Abroad (travel likely)Recruiting

Iowa City, United States

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Major Depressive Disorder · Treatment Resistant Depression

Abroad (travel likely)RecruitingPHASE3

Innsbruck, Austria · Bielefeld, Germany